Aurobindo Pharma is currently trading at RS. 1164.60, up by 7.60 points or 0.66% from its previous closing of RS. 1157.00 on the BSE.

The stock opened at RS. 1136.35 and recorded a high of RS. 1171.85 and a low of RS. 1136.35 during the session. So far, 24,147 shares have been traded on the counter.

Aurobindo, a BSE group 'A' stock with a face value of RS. 1, has touched a 52-week high of RS. 1592.55 on September 13, 2024, and a 52-week low of RS. 994.35 on April 7, 2025. Over the last week, the scrip’s high and low stood at RS. 1171.85 and RS. 1107.65 respectively. The company's current market capitalization is RS. 67422.36 crore.

Promoters hold 51.82% of the company’s shares, while Institutions and Non-Institutions hold 41.30% and 6.87% respectively.

In a strategic move, Aurobindo Pharma’s wholly owned subsidiary — Aurobindo Pharma USA Inc — has signed a definitive agreement with Lannett Seller Holdco, Inc to acquire 100% membership interest in Lannett Company LLC.

This acquisition supports Aurobindo’s strategy to expand its U.S. manufacturing presence by enhancing its domestic capabilities. The deal gives Aurobindo access to a complementary and profitable product portfolio, a growing CDMO (Contract Development and Manufacturing Organization) business, and a U.S.-based manufacturing facility with significant surplus capacity (425,000 sq. ft. and approximately 3.6 billion doses capacity), with scope for further expansion.

The product range focuses mainly on non-opioid controlled substances, especially ADHD therapeutics — a segment where Aurobindo currently has a limited presence. This acquisition will help Aurobindo diversify into a high-value, specialized therapeutic area and strengthen its position in the U.S. generics market.

Aurobindo Pharma is engaged in the manufacturing of pharmaceutical products including active pharmaceutical ingredients, intermediates, and generic formulations across therapeutic areas such as anti-infectives, pain management, oral and sterile antibiotics, and osteoporosis.